Claire Vanlemmens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Claire Vanlemmens has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Jérôme Dumortier
Hospices civils de Lyon, Edouard Herriot hospital, Department of Digestive Diseases, Lyon, France; Claude Bernard Lyon 1 University, Lyon, France
7 shared publications - Sébastien Dharancy
Service d'Hépato-Gastroentérologie, Lille University Hospital, Lille, France
7 shared publications - Georges-Philippe Pageaux
Hepato-gastroenterology Department, CHU Saint Eloi, Montpellier University
6 shared publications Jean Hardwigsen
Hepatogastroenterology Unit, CHU Timone, Marseille, France
6 shared publications- Nassim Kamar
Département de Néphrologie et Transplantation d'Organes CHU Rangueil Toulouse France
6 shared publications - Filomena Conti
CHU Pitié-Salpêtrière, AP-HP, Paris, France
5 shared publications
Latest Publications
- Open Access
- 9 January 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101722
Long-term outcomes and temporal trends following liver transplantation for chronic liver disease in the intensive care unit
- 9 January 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101722
Open AccessLong-term outcomes and temporal trends following liver transplantation for chronic liver disease in the intensive care unit
- 24 July 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (6) , 1401-1413
Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A French National Cohort Study Including 571 Patients
INTRODUCTION: Primary sclerosing cholangitis (PSC) may recur after liver transplantation (LT). We aimed to evaluate the incidence of recurrent PSC (rPSC), its characteristics, and risk factors, in a large cohort with long-term follow-up. METHODS: We conducted a nationwide multicenter retrospective study in France, including all adult patients transplanted for PSC from March 1985 to March 2019. Clinical, biological, and histological data were collected. Risk factors for rPSC were identified using a multivariate Cox-regression model. RESULTS: Five hundred seventy-one patients were included (389 males, 68.1%) with a median age at LT of 42.0 (interquartile range [IQR] 32.0–52.8). Median follow-up after LT was 7.4 years (IQR 3.6–12.6). Overall, rPSC occurred in 25.9% of patients; actuarial risk of developing rPSC at 5, 15, and 25 years was 15.6%, 37.9%, and 52.6%, respectively. The median time to rPSC was 4.9 years (IQR 2.3–8.9). The factors independently associated with rPSC were the presence of IBD (hazard ratio [HR] 1.97, 95% confidence interval [CI] 1.24–3.14), maintenance treatment with corticosteroids (HR 1.76, 95% CI 1.17–2.66), and younger age at LT (HR 1.02 per 1-year increase, 95% CI 1.01–1.03). Type of biliary anastomosis or preventive treatment with ursodeoxycholic acid had no impact on the incidence of rPSC. DISCUSSION: Our results from a large cohort with long-term follow-up strongly confirm that rPSC after LT is frequent. The only modifiable factor associated with rPSC was maintenance treatment with corticosteroids, which could therefore be discontinued in the absence of a specific extrahepatic indication.
- 24 July 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (6) , 1401-1413
Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A French National Cohort Study Including 571 Patients
INTRODUCTION: Primary sclerosing cholangitis (PSC) may recur after liver transplantation (LT). We aimed to evaluate the incidence of recurrent PSC (rPSC), its characteristics, and risk factors, in a large cohort with long-term follow-up. METHODS: We conducted a nationwide multicenter retrospective study in France, including all adult patients transplanted for PSC from March 1985 to March 2019. Clinical, biological, and histological data were collected. Risk factors for rPSC were identified using a multivariate Cox-regression model. RESULTS: Five hundred seventy-one patients were included (389 males, 68.1%) with a median age at LT of 42.0 (interquartile range [IQR] 32.0–52.8). Median follow-up after LT was 7.4 years (IQR 3.6–12.6). Overall, rPSC occurred in 25.9% of patients; actuarial risk of developing rPSC at 5, 15, and 25 years was 15.6%, 37.9%, and 52.6%, respectively. The median time to rPSC was 4.9 years (IQR 2.3–8.9). The factors independently associated with rPSC were the presence of IBD (hazard ratio [HR] 1.97, 95% confidence interval [CI] 1.24–3.14), maintenance treatment with corticosteroids (HR 1.76, 95% CI 1.17–2.66), and younger age at LT (HR 1.02 per 1-year increase, 95% CI 1.01–1.03). Type of biliary anastomosis or preventive treatment with ursodeoxycholic acid had no impact on the incidence of rPSC. DISCUSSION: Our results from a large cohort with long-term follow-up strongly confirm that rPSC after LT is frequent. The only modifiable factor associated with rPSC was maintenance treatment with corticosteroids, which could therefore be discontinued in the absence of a specific extrahepatic indication.
- 20 July 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 78, S473-S474
Long-term outcome following liver transplantation for chronic liver disease in intensive care unit: the French nationwide experience
- 20 July 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 78, S473-S474
Long-term outcome following liver transplantation for chronic liver disease in intensive care unit: the French nationwide experience
- Open Access
- 3 January 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (3) , 100668
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis
- 3 January 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (3) , 100668
Open AccessInevitability of disease recurrence after liver transplantation for NAFLD cirrhosis
- Open Access
- 27 December 2022
- Published by Wiley in Movement Disorders
- Vol. 38 (2) , 321-332
Diagnosis and Outcomes of Late‐Onset Wilson's Disease: A National Registry‐Based Study
Background: Wilson's disease (WD) is usually diagnosed in children and young adults; limited data exist on late‐onset forms.Objective: The aim was to characterize the clinical and paraclinical presentations, therapeutic management, and outcomes in patients with late‐onset WD.Methods: Patients diagnosed with WD after age 40 years were identified from the French Wilson's Disease Registry (FWDR). Clinical, laboratory, and imaging findings and treatment were reported at diagnosis and last follow‐up.Results: Forty‐five patients were identified (median age: 49, range: 40–64) and placed in three groups according to their clinical presentation: neurological (n = 20, median diagnostic delay: 20 months), hepatic (n = 13, diagnostic delay: 12 months), and family screening (n = 12), all confirmed genetically. Six neurological patients had an atypical presentation (1 torticollis, 2 writer's cramps, 2 functional movement disorders, and 1 isolated dysarthria), without T2/fluid‐attenuated inversion recovery brain magnetic resonance imaging (MRI) hyperintensities; 5 of 6 had no Kayser–Fleischer ring (KFR); 5 of 6 had liver involvement. In the neurological group, 84% of patients improved clinically, and 1 developed copper deficiency. In the hepatic group, 77% had cirrhosis; 6 patients required liver transplantation. In the screened group, 43% had mild liver involvement; 3 were not treated and remained stable; 24‐h urinary copper excretion was normal in 33% of patients at diagnosis.Conclusions: In the FWDR, late‐onset forms of WD affect 8% of patients, mostly with neurological presentations. Thirty percent of the neurological forms were atypical (isolated long‐lasting symptoms, inconspicuous brain MRI, no KFR). With personalized treatment, prognosis was good. This study emphasized that WD should be suspected at any age and even in cases of atypical presentation. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 27 December 2022
- Published by Wiley in Movement Disorders
- Vol. 38 (2) , 321-332
Open AccessDiagnosis and Outcomes of Late‐Onset Wilson's Disease: A National Registry‐Based Study
Background: Wilson's disease (WD) is usually diagnosed in children and young adults; limited data exist on late‐onset forms.Objective: The aim was to characterize the clinical and paraclinical presentations, therapeutic management, and outcomes in patients with late‐onset WD.Methods: Patients diagnosed with WD after age 40 years were identified from the French Wilson's Disease Registry (FWDR). Clinical, laboratory, and imaging findings and treatment were reported at diagnosis and last follow‐up.Results: Forty‐five patients were identified (median age: 49, range: 40–64) and placed in three groups according to their clinical presentation: neurological (n = 20, median diagnostic delay: 20 months), hepatic (n = 13, diagnostic delay: 12 months), and family screening (n = 12), all confirmed genetically. Six neurological patients had an atypical presentation (1 torticollis, 2 writer's cramps, 2 functional movement disorders, and 1 isolated dysarthria), without T2/fluid‐attenuated inversion recovery brain magnetic resonance imaging (MRI) hyperintensities; 5 of 6 had no Kayser–Fleischer ring (KFR); 5 of 6 had liver involvement. In the neurological group, 84% of patients improved clinically, and 1 developed copper deficiency. In the hepatic group, 77% had cirrhosis; 6 patients required liver transplantation. In the screened group, 43% had mild liver involvement; 3 were not treated and remained stable; 24‐h urinary copper excretion was normal in 33% of patients at diagnosis.Conclusions: In the FWDR, late‐onset forms of WD affect 8% of patients, mostly with neurological presentations. Thirty percent of the neurological forms were atypical (isolated long‐lasting symptoms, inconspicuous brain MRI, no KFR). With personalized treatment, prognosis was good. This study emphasized that WD should be suspected at any age and even in cases of atypical presentation. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 5 December 2022
- Published by Elsevier in JHEP Reports
- Vol. 5 (2) , 100644
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool
- 5 December 2022
- Published by Elsevier in JHEP Reports
- Vol. 5 (2) , 100644
Open AccessAFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool
- Open Access
- 1 September 2022
- Published by Wiley in Liver International
- Vol. 42 (11) , 2513-2523
Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study
Background and Aims: To report 5‐year outcomes of the CERTITUDE study.Methods: An observational study in patients with liver transplantation (LTx) compared the long‐term impact of immunosuppression (with/without a calcineurin inhibitor) on renal function, cancers, major cardiovascular events (MACEs) and other safety parameters. All patients completing the 6‐month SIMCER study were recruited and analysed according to treatment received at randomization and actual treatment received during the follow‐up.Results: Of the 143 enrolled patients, 119 completed the 5‐year follow‐up (everolimus [EVR], n = 55; tacrolimus [TAC], n = 64). The mean absolute change in estimated glomerular filtration rate was not statistically different between both groups (TAC, −15.53 ml/min/1.73 m2 and EVR, –14.56 ml/min/1.73 m2). In the treatment subgroups based on actual treatment received, renal function was preserved better in the EVR subgroup compared with other subgroups (p = .051). Treated biopsy‐proven acute rejection was higher in the EVR group (15.4% vs. 6.4%); however, the majority of events were mild in severity. MACE occurred in 9.2% vs. 14.1% of patients in the EVR and TAC groups respectively (p = .370). De novo cancer was reported in 14 and 5 patients in EVR and TAC groups respectively. Hepatocellular carcinoma (HCC) recurrence was observed in the TAC group alone (n = 4). Adverse events and treatment discontinuation owing to an adverse event were higher in the EVR group.Conclusions: The CERTITUDE study demonstrated that EVR‐ and TAC‐based regimens have comparable efficacy, safety and tolerability up to 5 years post‐LTx.
- 1 September 2022
- Published by Wiley in Liver International
- Vol. 42 (11) , 2513-2523
Open AccessFive‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study
Background and Aims: To report 5‐year outcomes of the CERTITUDE study.Methods: An observational study in patients with liver transplantation (LTx) compared the long‐term impact of immunosuppression (with/without a calcineurin inhibitor) on renal function, cancers, major cardiovascular events (MACEs) and other safety parameters. All patients completing the 6‐month SIMCER study were recruited and analysed according to treatment received at randomization and actual treatment received during the follow‐up.Results: Of the 143 enrolled patients, 119 completed the 5‐year follow‐up (everolimus [EVR], n = 55; tacrolimus [TAC], n = 64). The mean absolute change in estimated glomerular filtration rate was not statistically different between both groups (TAC, −15.53 ml/min/1.73 m2 and EVR, –14.56 ml/min/1.73 m2). In the treatment subgroups based on actual treatment received, renal function was preserved better in the EVR subgroup compared with other subgroups (p = .051). Treated biopsy‐proven acute rejection was higher in the EVR group (15.4% vs. 6.4%); however, the majority of events were mild in severity. MACE occurred in 9.2% vs. 14.1% of patients in the EVR and TAC groups respectively (p = .370). De novo cancer was reported in 14 and 5 patients in EVR and TAC groups respectively. Hepatocellular carcinoma (HCC) recurrence was observed in the TAC group alone (n = 4). Adverse events and treatment discontinuation owing to an adverse event were higher in the EVR group.Conclusions: The CERTITUDE study demonstrated that EVR‐ and TAC‐based regimens have comparable efficacy, safety and tolerability up to 5 years post‐LTx.
- Open Access
- 25 August 2022
- Published by Wiley in Liver International
- Vol. 42 (11) , 2428-2441
Liver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival
Background and Aims: Liver transplantation (LT) is the treatment of end‐stage non‐alcoholic liver disease (NAFLD), that is decompensated cirrhosis and/or complicated by hepatocellular carcinoma (HCC). Few data on long‐term outcome are available. The aim of this study was to evaluate overall patient and graft survivals and associated predictive factors.Method: This retrospective multicentre study included adult transplant patients for NAFLD cirrhosis between 2000 and 2019 in participating French‐speaking centres.Results: A total of 361 patients (69.8% of male) were included in 20 centres. The median age at LT was 62.3 years [57.4–65.9] and the median MELD score was 13.9 [9.1–21.3]; 51.8% of patients had HCC on liver explant. Between 2004 and 2018, the number of LT for NAFLD cirrhosis increased by 720%. A quarter of the patients had cardiovascular history before LT. Median follow‐up after LT was 39.1 months [15.8–72.3]. Patient survival at 1, 5 and 10 years after LT was 89.3%, 79.8% and 68.1% respectively. The main causes of death were sepsis (37.5%), malignancies (29.2%) and cardiovascular events (22.2%). In multivariate analysis, three risk factors for overall mortality after LT were recipient pre‐LT BMI < 32 kg/m2 at LT time (OR: 2.272; p = .012), pre‐LT angioplasty during CV check‐up (OR: 2.916; p = .016), a combined donor and recipient age over 135 years (OR: 2.020; 95%CI: p = .035).Conclusion: Survival after LT for NAFLD cirrhosis is good at 5 years. Donor and recipient age, and cardiovascular history, are major prognostic factors to consider.
- 25 August 2022
- Published by Wiley in Liver International
- Vol. 42 (11) , 2428-2441
Open AccessLiver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival
Background and Aims: Liver transplantation (LT) is the treatment of end‐stage non‐alcoholic liver disease (NAFLD), that is decompensated cirrhosis and/or complicated by hepatocellular carcinoma (HCC). Few data on long‐term outcome are available. The aim of this study was to evaluate overall patient and graft survivals and associated predictive factors.Method: This retrospective multicentre study included adult transplant patients for NAFLD cirrhosis between 2000 and 2019 in participating French‐speaking centres.Results: A total of 361 patients (69.8% of male) were included in 20 centres. The median age at LT was 62.3 years [57.4–65.9] and the median MELD score was 13.9 [9.1–21.3]; 51.8% of patients had HCC on liver explant. Between 2004 and 2018, the number of LT for NAFLD cirrhosis increased by 720%. A quarter of the patients had cardiovascular history before LT. Median follow‐up after LT was 39.1 months [15.8–72.3]. Patient survival at 1, 5 and 10 years after LT was 89.3%, 79.8% and 68.1% respectively. The main causes of death were sepsis (37.5%), malignancies (29.2%) and cardiovascular events (22.2%). In multivariate analysis, three risk factors for overall mortality after LT were recipient pre‐LT BMI < 32 kg/m2 at LT time (OR: 2.272; p = .012), pre‐LT angioplasty during CV check‐up (OR: 2.916; p = .016), a combined donor and recipient age over 135 years (OR: 2.020; 95%CI: p = .035).Conclusion: Survival after LT for NAFLD cirrhosis is good at 5 years. Donor and recipient age, and cardiovascular history, are major prognostic factors to consider.
- 1 October 2021
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 64 (10) , 104305
ATP7B variant spectrum in a French pediatric Wilson disease cohort
- 1 October 2021
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 64 (10) , 104305
ATP7B variant spectrum in a French pediatric Wilson disease cohort
- 1 March 2009
- Published by Elsevier in Gastroentérologie Clinique Et Biologique
- Vol. 33 (3) , A17-17
CO.34 Transplantation hépatique (TH) de patients avec cirrhose alcoolique (CA) alcoolisés le jour de la greffe : étude cas-contrôle
- 1 March 2009
- Published by Elsevier in Gastroentérologie Clinique Et Biologique
- Vol. 33 (3) , A17-17
CO.34 Transplantation hépatique (TH) de patients avec cirrhose alcoolique (CA) alcoolisés le jour de la greffe : étude cas-contrôle